Pooled Platelet-Rich Plasma Lysate Therapy Increases Synoviocyte Proliferation and Hyaluronic Acid Production While Protecting Chondrocytes From Synoviocyte-Derived Inflammatory Mediators.
Authors: Gilbertie Jessica M, Long Julie M, Schubert Alicia G, Berglund Alix K, Schaer Thomas P, Schnabel Lauren V
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Pooled platelet lysate preparations offer a promising alternative to autologous PRP for osteoarthritis management, circumventing the immunogenicity concerns and biological variability that limit traditional platelet-rich plasma whilst remaining amenable to batch production and frozen storage. Using an in-vitro model of the inflamed joint, researchers exposed equine synoviocytes to inflammatory triggers (interleukin-1β or lipopolysaccharide) before treating them with either platelet-poor plasma lysate or platelet-rich plasma lysate, then assessed how the resulting conditioned media affected chondrocyte behaviour. Treatment with PRP-L significantly increased synoviocyte proliferation and hyaluronic acid production, whilst chondrocytes subsequently exposed to this conditioned media demonstrated upregulated expression of collagen II and aggrecan alongside suppressed matrix metallopeptidase-13 expression—a profile suggesting protection against catabolic degradation. These findings indicate that pooled PRP-L may operate through dual mechanisms: supporting synovial tissue homeostasis whilst simultaneously dampening the chondrocyte damage ordinarily driven by inflamed synovial mediators. For practitioners considering intra-articular therapeutics, the capacity to manufacture and store standardised lysate batches represents a significant practical advantage, though further research to establish optimal dosing, timing, and clinical efficacy in living joints remains essential before widespread adoption.
Read the full abstract on PubMed
Practical Takeaways
- •Pooled platelet lysate preparations may offer a standardized, off-the-shelf alternative to autologous PRP for treating joint inflammation in horses with potential chondroprotective benefits
- •This in-vitro evidence supports further clinical investigation, but results cannot yet be applied to live horses—clinical trials are needed before use in practice
- •The mechanism appears to involve modulation of inflammatory mediators and growth factor delivery rather than simple anti-inflammatory action
Key Findings
- •Pooled platelet-rich plasma lysate (PRP-L) increased equine synoviocyte proliferation and hyaluronic acid production compared to controls
- •PRP-L treatment of inflamed synoviocytes resulted in increased IL-6 production and altered inflammatory mediator profiles
- •Chondrocytes exposed to PRP-L-treated synoviocyte conditioned media showed increased collagen type II and aggrecan gene expression with decreased MMP-13 expression, indicating chondroprotective effects
- •Pooled allogeneic PRP-L offers advantages over autologous PRP including reduced variability, no immunogenicity concerns, and frozen storage capability